Late-onset neutropenia following rituximab

被引：8
作者：
McLaughlin, Peter [1 ]
机构：
[1] Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
LEUKEMIA & LYMPHOMA | 2006年 / 47卷 / 06期
关键词：
D O I：
10.1080/10428190600649349
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：965 / 966
页数：2
相关论文
共 13 条
[1]  
Cabanillas F, 2005, BLOOD, V106, p687A
[2]   Delayed-onset peripheral blood cytopenia after rituximab: Frequency and risk factor assessment in a consecutive series of 77 treatments [J].
Cattaneo, Chiara ;
Spedini, Pierangelo ;
Casari, Salvatore ;
Re, Alessandro ;
Tucci, Alessandra ;
Borlenghi, Erika ;
Ungari, Marco ;
Ruggeri, Giulia ;
Rossi, Giuseppe .
LEUKEMIA & LYMPHOMA, 2006, 47 (06) :1013-1017
[3]   CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. [J].
Coiffier, B ;
Lepage, E ;
Brière, J ;
Herbrecht, R ;
Tilly, H ;
Bouabdallah, R ;
Morel, P ;
Van den Neste, E ;
Salles, G ;
Gaulard, P ;
Reyes, F ;
Gisselbrecht, C .
NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (04) :235-242
[4]   Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden:: clinical and molecular evaluation [J].
Colombat, P ;
Salles, G ;
Brousse, N ;
Eftekhari, P ;
Soubeyran, P ;
Delwail, V ;
Deconinck, E ;
Haïoun, C ;
Foussard, C ;
Sebban, C ;
Stamatoullas, A ;
Milpied, N ;
Boué, F ;
Taillan, B ;
Lederlin, P ;
Najman, A ;
Thièblemont, C ;
Montestruc, F ;
Mathieu-Boué, A ;
Benzohra, A ;
Solal-Céligny, P .
BLOOD, 2001, 97 (01) :101-106
[5]   B-cell recovery following rituximab-based therapy is associated with perturbations in stromal derived factor-1 and granulocyte homeostasis [J].
Dunleavy, K ;
Hakim, F ;
Kim, HK ;
Janik, JE ;
Grant, N ;
Nakayama, T ;
White, T ;
Wright, G ;
Kwak, L ;
Gress, R ;
Tosato, G ;
Wilson, WH .
BLOOD, 2005, 106 (03) :795-802
[6]   The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas:: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group [J].
Forstpointner, R ;
Dreyling, M ;
Repp, R ;
Hermann, S ;
Hänel, A ;
Metzner, B ;
Pott, C ;
Hartmann, F ;
Rothmann, F ;
Rohrberg, R ;
Böck, HP ;
Wandt, H ;
Unterhalt, M ;
Hiddemann, W .
BLOOD, 2004, 104 (10) :3064-3071
[7]   Severe and prolonged myeloid haematopoietic toxicity with myelodysplastic features following alemtuzumab therapy in patients with peripheral T-cell lymphoproliferative disorders [J].
Gibbs, SDJ ;
Westerman, DA ;
McCormack, C ;
Seymour, JF ;
Prince, HM .
BRITISH JOURNAL OF HAEMATOLOGY, 2005, 130 (01) :87-91
[8]   Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone:: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group [J].
Hiddemann, W ;
Kneba, M ;
Dreyling, M ;
Schmitz, N ;
Lengfelder, E ;
Schmits, R ;
Reiser, M ;
Metzner, B ;
Harder, H ;
Hegewisch-Becker, S ;
Fischer, T ;
Kropff, M ;
Reis, HE ;
Freund, M ;
Wörmann, B ;
Fuchs, R ;
Planker, M ;
Schimke, J ;
Eimermacher, H ;
Trümper, L ;
Aldaoud, A ;
Parwaresch, R ;
Unterhalt, M .
BLOOD, 2005, 106 (12) :3725-3732
[9]   Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study [J].
Keating, MJ ;
Flinn, I ;
Jain, V ;
Binet, JL ;
Hillmen, P ;
Byrd, J ;
Albitar, M ;
Brettman, L ;
Santabarbara, P ;
Wacker, B ;
Rai, KR .
BLOOD, 2002, 99 (10) :3554-3561
[10]   CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma [J].
Marcus, R ;
Imrie, K ;
Belch, A ;
Cunningham, D ;
Flores, E ;
Catalano, J ;
Solal-Celigny, P ;
Offner, F ;
Walewski, J ;
Raposo, J ;
Jack, A ;
Smith, P .
BLOOD, 2005, 105 (04) :1417-1423
12